1Su JB, Barbe F, Houel R, et al. Preserved vasodilator effect of bradykinin in dogs with heart failure. Circulation, 1998, 98(25) :2911-8.
2Barbe F, Su JB, Guyene TT, et al. Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure. Am J Physiol, 1996, 270: H1985- 92.
3Hornig B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure.Eur Heart J, 1998, 19(Suppl G):48-53.
4Maguire SM, McAuley D, McGurk C, et al. Bradykinin infusion in chronic cardiac failure and the effects of captopril. Eur J Heart Fail, 2001, 3(6) :671-7.
5Weber KT, Sun Y, Guarda E, et al. Myocardiol fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Eur Heart J, 1995,16(Suppl C) :24-8.
6Weber KT. Extracellular matrix remolding in heart failure: a role of de novo angiotension Ⅱ generation. Circulation, 1997,96(11) : 4065-82.
7Weber KT. Cardioreparation in hypertensive heart disease.Hypertension, 2001, 38(3pt2) : 588 - 91.
8Emanueli C, Maestri R, Corradi D, et al. Dilated and failing cardiomyopathy in bradykinin - receptor knockout mice. Circulation, 1999, 100: 2359-65.
9Kuoppala A, Shiota N, Kokkonen JO, et al. Down- regulation of cardioprotective bradykinin type - 2 receptors in the left ventricle of patients with end - stage heart failure. J Am Coil Cardiol, 2002, 40(1):119-25.
10Meneton P, Blocl - Faureu M, Hagege A, et al. Targeted disruption of the tissue kallikrien gene triggers cardiac abnormalities typical of a dilated cardiomyopathy. Hypertension, 1999,34: 333.
